Daniel Layish, MD
Pulmonary Disease · Orlando, FLNPI 1659350320
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,135 of the $61,887 with a category attached, or 69.7%. It is spread thinly across 51 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2019 at $29,109 and has fallen 81.0% since, to $5,526 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 625 payments — averaging $99.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$14K
- Grifols USA, LLC$7K
- Bayer$7K
- Mylan Specialty L.p.$5K
- Viiv Healthcare Company$4K
- Genentech USA, Inc.$4K
- plus $20K from 45 others
Across 193 payments — averaging $8857.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$636K
- Vertex$535K
- First Wave Biopharma, Inc.$249K
- United Therapeutics Corporation$130K
- Sanofi US Services Inc.$36K
- Boehringer Ingelheim$35K
- plus $87K from 7 others
What the payments were for
- Consulting fees$2,0003%
- Speaking & faculty fees$43,13570%
- Grants$1,0002%
- Travel & lodging$1,5012%
- Food & beverage$13,21121%
- Education$1,0132%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$12,221
- Adempas$7,067
- Prolastin-C Liquid$5,237
- Yupelri$4,773
- Esbriet$3,664
- ZEPBOUND$3,450
- SUNOSI$2,900
- Prolastin-C$1,923
- BOTOX$1,000
- ANORO$837
- LUMRYZ$200
- HawkOne$157
- FLOWTRIEVER CATHETER, S$138
- CT THROMBECTOMY SYSTEM KIT$138
- XOLAIR$125
- Wakix$125
- TOBI Podhaler$122
- RELIZORB$106
- inCourage$100
How this compares
$61,887 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 475 | $13,010,153 |
| ZenpepLipase/Protease/Amylase | 104 | $949,569 |
| AdempasRiociguat | 68 | $947,588 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 56 | $742,710 |
| OfevNintedanib Esylate | 52 | $681,413 |
| CaystonAztreonam Lysine | 53 | $633,448 |
| UptraviSelexipag | 27 | $515,063 |
| OpsumitMacitentan | 32 | $401,637 |
| CreonLipase/Protease/Amylase | 75 | $382,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 381 | $349,536 |
| KalydecoIvacaftor | 12 | $310,732 |
| Tyvaso DpiTreprostinil | 12 | $261,941 |
| PertzyeLipase/Protease/Amylase | 47 | $226,602 |
| XywavSodium,calcium,mag,pot Oxybate | 11 | $218,623 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $205,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Kalydeco | $273 | $13,320,884487 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi | $1,542 | $1,118,43775 claims |
| Aimmune Therapeutics, Inc.Zenpep | $81 | $949,569104 claims |
| BayerAdempas | $7,140 | $947,58868 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $725 | $797,172200 claims |
| Grifols USA, LLCProlastin C | $7,249 | $742,71056 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $14,279 | $658,017613 claims |
| GileadCayston | $481 | $633,44853 claims |
| AbbVieCreon | $1,316 | $382,93975 claims |
| Digestive Care, Inc.Pertzye | $28 | $226,60247 claims |
| Insmed, Inc.Arikayce | $823 | $205,74614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $75 | $196,86815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Orlando
- Ali JiwaniOrlando$859K
- Junaid MalikOrlando$429K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.